Unicycive Therapeutics (UNCY) EBT (2020 - 2026)
Unicycive Therapeutics posted quarterly EBT of -$8.0 million for Q1 2026, down 3.41% year-on-year from -$8.3 million in Q1 2025, and down 16.57% on a QoQ basis from -$6.9 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of EBT data on file, last reported at -$8.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 3.41% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$28.8 million (up 2.4% YoY), and the FY2025 full-year result was -$28.6 million, up 7.6% from the prior year.
- EBT for Q1 2026 stood at -$8.0 million, down from -$6.9 million in the prior quarter.
- Across five years, EBT topped out at -$3.5 million in Q1 2022 and bottomed at -$9.2 million in Q1 2024.
- The 5-year median for EBT is -$6.2 million (2023), against an average of -$6.2 million.
- The widest annual swing landed in 2022, when EBT sank 259.82%; it then rose 23.05% in 2025.
- A 5-year view of EBT shows it stood at -$5.3 million in 2022, then fell by 16.22% to -$6.2 million in 2023, then tumbled by 44.82% to -$9.0 million in 2024, then grew by 23.05% to -$6.9 million in 2025, then fell by 16.57% to -$8.0 million in 2026.
- The last three EBT figures came in at -$8.0 million (Q1 2026), -$6.9 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -8.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.04 Mn |
| Dec 31, 2025 | -6.90 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.82 Mn |
| Mar 31, 2025 | -7.78 Mn |
| Dec 31, 2024 | -8.97 Mn |
| Sep 30, 2024 | -5.85 Mn |
| Jun 30, 2024 | -6.96 Mn |
| Mar 31, 2024 | -9.16 Mn |
| Dec 31, 2023 | -6.19 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -4.12 Mn |
| Mar 31, 2023 | -4.20 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.56 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -4.77 Mn |
| Jun 30, 2021 | -1.10 Mn |
| Mar 31, 2021 | -983,000.00 |
| Dec 31, 2020 | -880,000.00 |
| Sep 30, 2020 | -702,000.00 |
| Jun 30, 2020 | -338,000.00 |